Method of predicting a predisposition to qt prolongation
AssigneeVanda Pharmaceuticals Inc.
InventorsChristian Lavedan, Simona Volpi, Louis Licamele
Life of this patent
Estimating the term…
Abstract
The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Claims22
A method of administering to an individual a compound capable of prolonging the individual's QT interval, the method comprising:
- determining at least a portion of an individual's FAM13A1 (family with sequence similarity 13, member A1) gene sequence;
- and
- in the case that a portion of the individual's FAM13A1 gene sequence is associated with an increased risk of QT prolongation, administering to the individual a quantity of the compound less than would be administered to an individual having a FAM13A1 gene sequence not associated with an increased risk of QT prolongation.
(canceled)
A method of determining whether an individual is predisposed to prolongation of the QT interval, the method comprising:
- determining at least a portion of an individual's FAM13A1 (family with sequence similarity 13, member A1) gene sequence.
A method of administering a compound capable of prolonging a QT interval to an individual suffering from long QT syndrome (LQTS), the method comprising:
- determining at least a portion of an individual's FAM13A1 (family with sequence similarity 13, member A1) gene sequence;
- and
- administering to the individual a quantity of the compound based on the individual's FAM13A1 gene sequence.
(canceled)
19-21. (canceled)
24-33. (canceled)
Dependencies are inferred from the claim text.